Johnson & Johnson (NYSE:JNJ) Shares Sold by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 0.4% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 68,218 shares of the company’s stock after selling 301 shares during the quarter. Johnson & Johnson makes up approximately 3.5% of Roberts Glore & Co. Inc. IL’s investment portfolio, making the stock its 4th largest position. Roberts Glore & Co. Inc. IL’s holdings in Johnson & Johnson were worth $12,090,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Personal CFO Solutions LLC lifted its holdings in Johnson & Johnson by 1.0% during the 1st quarter. Personal CFO Solutions LLC now owns 14,407 shares of the company’s stock valued at $2,553,000 after purchasing an additional 149 shares during the last quarter. Lloyd Advisory Services LLC. lifted its holdings in Johnson & Johnson by 2,021.4% during the 1st quarter. Lloyd Advisory Services LLC. now owns 891 shares of the company’s stock valued at $158,000 after purchasing an additional 849 shares during the last quarter. MBL Wealth LLC acquired a new stake in Johnson & Johnson during the 1st quarter valued at $983,000. CFO4Life Group LLC lifted its holdings in Johnson & Johnson by 4.0% during the 1st quarter. CFO4Life Group LLC now owns 12,524 shares of the company’s stock valued at $2,220,000 after purchasing an additional 484 shares during the last quarter. Finally, Spinnaker Trust lifted its holdings in Johnson & Johnson by 1.4% during the 1st quarter. Spinnaker Trust now owns 47,615 shares of the company’s stock valued at $8,439,000 after purchasing an additional 643 shares during the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. SVB Leerink lowered their price objective on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Morgan Stanley increased their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Wells Fargo & Company raised their price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $173.68 on Wednesday. The stock’s 50-day simple moving average is $176.04 and its 200 day simple moving average is $174.37. The firm has a market capitalization of $457.02 billion, a PE ratio of 25.28, a price-to-earnings-growth ratio of 3.27 and a beta of 0.63. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period last year, the firm posted $2.48 earnings per share. Johnson & Johnson’s revenue was up 3.0% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.60%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.

Insider Activity

In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.